Therapeutic behavior to follow in the following clinical case: Treatment of type 2 diabetes;Conducta terapéutica a seguir en el siguiente caso clínico: tratamiento de la diabetes tipo 2

Revista Clinica Espanola

Volumn 210, Issue 1, 2010, Pages 23-25

  Mateos, Lourdes ^a   Herraez Garcia J ^a   Martin Oterino, J A ^a   Sánchez Rodríguez, Ángel ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Diabetes; Hypertensi n; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CREATININE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT REFERRAL; PHYSICAL EXAMINATION; SIBLING; SUDDEN DEATH; TRIACYLGLYCEROL BLOOD LEVEL; WALKING; WEIGHT GAIN; WEIGHT REDUCTION; MIDDLE AGED; TIME;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MIDDLE AGED; TIME FACTORS;

EID: 73449139048     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2009.04.003     Document Type: Note

References (11)

1. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Rury R., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care 29 (2006) 1963-1972
2. Type 2 diabetes. National clinical guideline for management in primary and secondary care (update). 2008. Disponible en: http://www.nice.org.uk/nicemedia/pdf/CG66diabetesfullguideline.pdf
3. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Colman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009) 193-203
4. Levovitz H. Insulin resistance- a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 8 (2006) 2337-249
5. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferators-activated receptor gamma agonist. J Clin Invest 106 (2000) 467-472
6. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy (for the ADOPT Study Group). N Engl J Med 355 (2006) 2427-2443
7. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
8. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) of the European Society of Cardiology (ESC). J Hypertension (2007) 1105-1187
9. Dormandy J.A., Charbonnel B., Eckland D.J., Erdman E., Massi Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-ACTIVE Study: A randomized controlled trial. Lancet 366 (2005) 1279-1289
10. Nissen S.E., and Wolski K. Effect of rosiglitazones on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med 356 (2007) 2457-71
11. Home P.H., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes. An interim analysis. N Engl J Med 357 (2007) 28-38